TARGETING OF PLASMINOGEN ACTIVATORS IN MYOCARDIAL INFARCT

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1988
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
8069
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Proteins International
1858 Star Batt Dr, Rochester, MI, 48063
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
THE LONG-TERM OBJECTIVE OF THIS PROJECT IS THE DEVELOPMENT AND CHARACTERIZATION OF CONJUGATES BETWEEN PLASMINOGEN ACTIVATORS (UROKINASE, TISSUE PLASMINOGEN ACTIVATOR, SINGLE CHAIN UROKINASE) AND MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN CARDIAC HEAVY CHAIN MYOSIN. THIS TYPE OF CONJUGATE BYSELECTIVELY TARGETING THE PLASMINOGEN ACTIVATOR TO DAMAGED MYOCYTES IN THE AREA OF THE THROMBUS, SHOULD SIGNIFICANTLY REDUCE SYSTEMIC PLASMINOGEN ACTIVATION AND THE ASSOCIATED DELETERIOUS EFFECTS. THE INITIAL PHASE OF THIS RESEARCH WILL BE DIRECTED TOWARD COVALENTLY COUPLING UROKINASE WITH ANTI-MYOSIN ANTIBODIES AND CHARACTERIZING THE RESULTING CONJUGATES FOR PLASMINOGEN ACTIVATING ACTIVITY AND MYOSIN BINDING AVIDITY. IN VITRO TESTING OF THE CONJUGATES WILL BE DONE TO DETERMINE THE DISTANCE FROM THE MYOSIN BINDING SITES WHEREIN PLASMIN PRODUCED BY THE CONJUGATE CAN EFFECT FIBRINOLYSIS. IN ADDITION TO POTENTIAL DEVELOPMENT OF AN IMPROVED THROMBOLYTIC AGENT FOR CLINICAL USE, THESE STUDIES MAY LEAD TO THE DEVELOPMENT OF A MORE GENERAL APPROACH FOR TARGETING SPECIFIC ENZYMES TO PATHOLOGICAL SITES.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government